Table 1. Characteristics of patients according to the presence of haematuria.
| HP (n = 31) | P (n = 40) | All (n = 71) | P value | |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Age (years) | 62.9±16.9 | 66.9±13.0 | 65.1±14.85 | 0.27 |
| Gender (Male, %) | 20(57.5) | 23(64.5) | 43(56.3) | 0.68 |
| Hypertension (Yes, %) | 26 (83.9) | 36 (90) | 62 (87.3) | 0.34 |
| Number of antihypertensive drugs (n) | 2.1±1.5 | 2.7±1.5 | 2.5±1.5 | 0.11 |
| RAAS inhibitors (Yes, %) | 17(50) | 22 (61.1) | 39 (55.7) | 0.24 |
| Diabetes Mellitus (Yes, %) | 12 (38.7) | 14 (35) | 26 (36.6) | 0.47 |
| Body mass index (kg/m2) | 27.2±4.7 | 29.6±6.6 | 28.5±5.9 | 0.09 |
| Charlson comorbidity index | 6.03±2.52 | 5.18±1.75 | 5.55±2.15 | 0.10 |
| Mean number of eGFR determinations per patient (n) | 7.7±3.2 | 7.3±2.5 | 7.5±2.7 | 0.50 |
| Follow up (months) | 11.56±5.74 | 12.17±5.1 | 11.9±5.35 | 0.79 |
| Age (years) | 62.9±16.9 | 66.9±13.0 | 65.1±14.85 | 0.27 |
| Baseline levels | ||||
| Serum creatinine (mg/dL) | 3.32±0.64 | 3.13±0.66 | 3.2±0.65 | 0.23 |
| eGFR (mL/min/1.73m2) | 19.25±5.47 | 19.78±4.63 | 19.6±4.99 | 0.65 |
| Serum phosphate (mg/dL) | 5.1 ±5.9 | 4.1±0.65 | 4.5±3.9 | 0.38 |
| Serum PTH(ng/L) | 203[101, 421] | 166[124, 283] | 185[115, 310] | 0.83 |
| Serum calcium (mg/dL) | 8.67±0.63 | 8.4±0.77 | 8.5±0.7 | 0.10 |
| Serum haemoglobin (g/dL) | 12.4±1.7 | 11.8±1.4 | 12.1±1.56 | 0.11 |
| Proteinuria (g/24 h) | 1.11±1.69 | 0.89±1.38 | 0.98±1.51 | 0.55 |
| Urinary excretion of urea nitrogen (g/24h) | 16.86±5.82 | 18.08±5.83 | 17.5±5.8 | 0.39 |
| Mean determination during follow up | ||||
| Proteinuria (g/24 h) | 1.06±1.33 | 0.99±1.27 | 1.02±1.29 | 0.81 |
| Serum Phosphate (mg/dL) | 4.17±0.77 | 3.98±0.56 | 4.07±0.66 | 0.22 |
| Serum PTH (ng/L) | 205[118, 466] | 216[173, 322] | 208[171, 333] | 0.83 |
| Mean Annual eGFR slope (mL/min/1.73m2/year) | -3.76±8.68 | 0.92±9.49 | -1.12±9.38 | 0.03 |
Results are expressed as mean ± SD, n(%) or median [IQR]. HP, Haemoproteinuria; P, proteinuria alone; eGFR, estimated glomerular filtration rate; PTH, parathyroid hormone; RAAS inhibitors, renin angiotensin aldosterone system inhibitors.